| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000042443 |
| Receipt No. | R000045593 |
| Scientific Title | Psychological barriers of opioid analgesics and pain in patients with advanced recurrent cancer - A multicenter cohort study |
| Date of disclosure of the study information | 2020/11/15 |
| Last modified on | 2022/05/16 (Ver. 11) |
| Basic information | ||
| Public title | Psychological barriers of opioid analgesics and pain in patients
with advanced recurrent cancer - A multicenter cohort study |
|
| Acronym | BAROC study
|
|
| Scientific Title | Psychological barriers of opioid analgesics and pain in patients
with advanced recurrent cancer - A multicenter cohort study |
|
| Scientific Title:Acronym | BAROC study
|
|
| Region |
|
|
| Condition | ||||||||||
| Condition | advanced recurrent cancer | |||||||||
| Classification by specialty |
|
|||||||||
| Classification by malignancy | Malignancy | |||||||||
| Genomic information | NO | |||||||||
| Objectives | |
| Narrative objectives1 | To determine the presence of psychological resistance to strong opioid analgesics before and after the introduction of opioid analgesics in patients with advanced recurrent cancer, and the relationship between the speed with which pain improves and the dose of analgesic medication. |
| Basic objectives2 | Pharmacodynamics |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Total JBQ-II score, subscales: barriers related to physiological effects (distrust of symptomatic treatment), barriers related to fatalism (fatalistic resignation), barriers related to communication (disinclination), barriers related to harmful effects (fear of side effects), barriers related to disease progression (from disease We calculated the mean and point estimates of the scores of the (escape defense) scale, and estimated the 95% confidence intervals. In addition, we will classify all observations into groups using the PGI-S, which was installed as an anchor, and estimate the 95% confidence intervals by calculating the mean and point estimates of the total score and the score of the association scale in each group. |
| Key secondary outcomes | Scores of JBQ-II for baseline, JBQ-II for Visit 2 and DRS
Change in baseline and Visit 2 in JBQ-II scores Percentage of PPGs achieved through Day 7 The JBQ-II score or Anchor was used to classify the groups, and the differences in DRS score and PPG achievement rate between the two groups were estimated and tested. |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Patients with distant metastases or diagnosed with advanced recurrent cancer
2. Patients using strong opioid analgesics for cancer pain for the first time 3. Patients with most intense pain NRS (Numeric rating scale) of 4 or more in the past 24 hours 4. Patients with written consent to participate in the study |
|||
| Key exclusion criteria | 1. Patients who are considered difficult to collect ePRO (e.g., do not have a smartphone or cannot use a tablet)
2. Patients who have cognitive problems that make it difficult to respond to PROs 3. Patients who have mental health issues that make it difficult to answer the PROs 4. Patients whose primary mechanism of pain is neuropathic pain 5. Patients deemed unfit by a physician |
|||
| Target sample size | 50 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Yokohama City University Medical Center | ||||||
| Division name | Anesthesiology | ||||||
| Zip code | 232-0024 | ||||||
| Address | 4-57, Urafune-cho, Minami-ku, Yokohama | ||||||
| TEL | 0452615656 | ||||||
| yanaizumi0330@yahoo.co.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Yokohama City University Medical Center | ||||||
| Division name | Pharmacy | ||||||
| Zip code | 232-0024 | ||||||
| Address | 4-57, Urafune-cho, Minami-ku, Yokohama | ||||||
| TEL | 0452615656 | ||||||
| Homepage URL | |||||||
| take1201@yokohama-cu.ac.jp | |||||||
| Sponsor | |
| Institute | Tokyo University of Pharmacy and Life Sciences |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Self-funding |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | YCU Center for Novel and Exploratory Clinical Trials |
| Address | 1-1-1, Fukuura, Kanazawa-ku, Yokohama |
| Tel | 0453707933 |
| rinri@yokohama-cu.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 横浜市立大学附属市民総合医療センター(神奈川県)、国立がん研究センター東病院(千葉県)、東京医科大学病院(東京都)、横浜南共済病院(神奈川県)、亀田総合病院(千葉県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | Study type: Multicenter prospective observational study
Scores of JBQ-II for baseline, JBQ-II for Visit 2 and DRS Change in baseline and Visit 2 in JBQ-II scores Percentage of PPGs achieved through Day 7 The JBQ-II score or Anchor was used to classify the groups, and the differences in DRS score and PPG achievement rate between the two groups were estimated and tested. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000045593 |